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Objective: This study assessed midterm results of emergency endovascular stent–graft-
ing for patients with life-threatening complications of acute type B aortic dissection.
Methods: Between November 1996 and June 2004, 16 patients with complicated acute
type B aortic dissections (mean age 57 years, range 16–88 years) underwent
endovascular stent–grafting within 48 hours of presentation. Complications included
contained rupture, hemothorax, refractory chest pain, and severe visceral or lower
limb ischemia. Stent–graft types included custom-made first-generation endografts
and second-generation commercial stent–grafts (Gore Excluder or TAG; W. L. Gore
& Associates, Inc, Flagstaff, Ariz.). Follow-up was 100% complete, averaged 36 6
36 months, and included postprocedural surveillance computed tomographic scans.
Results: Early mortality was 25%6 11% (70% confidence limit), with no late deaths.
No new neurologic complications occurred. According to the latest scan, 4 patients
(25%) had complete thrombosis of the false lumen; the lumen was partially throm-
bosed in 6 patients (38%). Distal aortic diameter was increased in only 1 patient.
Actuarial survival at 1 and 5 years was 73% 6 11%; freedom from treatment failure
(including aortic rupture, device fault, reintervention, aortic death, or sudden, unex-
plained late death) was 67% 6 14% at 5 years.
Conclusion: With follow-up to 9 years, endovascular stent–grafting for patients with
complicated acute type B aortic dissection conferred benefit. Consideration of emer-
gency stent–grafting may improve the dismal outlook for these patients; future refine-
ments in stent–graft design and technology and earlier diagnosis and intervention
should be associated with improved results.
T
he feasibility of endovascular stent–graft repair for descending thoracic aortic
pathology was established more than 15 years ago.1 Subsequently, stent–grafts
have been used to treat aneurysmal disease, intramural hematoma with penetrat-
ing ulcer, traumatic aortic disruption, and acute or chronic aortic dissection.2,3 What re-
main unknown are the long-term efficacy and durability of stent–grafts associated with
these various disease entities. Because it is less invasive than a conventional open surgi-
cal procedure,4 the endovascular approach for repair of descending thoracic aortic aneu-
rysms is associated with less early postprocedural morbidity and mortality.5 Although
complications occur, they are usually manageable by endovascular means, with the ne-
cessity for surgical conversion being infrequent.6 Complicated acute type B aortic dissec-
tion is perhaps the most promising application for endovascular stent–grafting,6 because
surgical repair has been accompanied by high morbidity and mortality.7-14 Nonetheless,
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CDAbbreviations and Acronyms
CTA 5 computed tomographic angiography
PIT 5 primary intimal tear
acute type B dissection remains a challenging endovascular
target, in that it requires coverage of the primary intimal
tear (PIT) in addition to correction associated end-organ mal-
perfusion, whether the ischemic mechanism be static or dy-
namic.15,16
Although several reports of patients with aortic dissection
treated with stent–grafts have been published, these mixed se-
ries frequently commingled type A and type B dissections,
acute and chronic dissections, or complicated and uncompli-
cated cases; further, clinical follow-up has been short, hinder-
ing critical assessment of results. We report our midterm stent–
graft results in patients with acute type B aortic dissection with
life-threatening complications.
Materials and Methods
From October 1996 to June 2004, a total of 16 consecutive patients
were treated by a multidisciplinary team (interventional radiology
and cardiovascular surgery) at Stanford University. Emergency en-
dovascular treatment was carried out with first-generation, custom-
fabricated devices initially and then later with a Gore Excluder or
TAG commercial stent–graft (W. L. Gore & Associates, Inc, Flag-
staff, Ariz) under a physician-sponsored IDE investigational proto-
col approved by the Stanford University School of Medicine
institutional review board. Informed consent was obtained from
each patient or a responsible relative. Computed tomographic angi-
ography (CTA) confirmed the diagnosis, assisted in surgical plan-
ning, and was used for follow-up. All patients were initially
admitted to the cardiovascular surgical intensive care unit for stabi-
lization, usually because of threatened rupture, persistent pain, rapid
expansion, or critical visceral or lower limb ischemia.
Cases of acute type B aortic dissections were judged to be com-
plicated if one or more of the following four clinical problems were
present: (1) ongoing intractable chest pain, despite maximal medical
therapy; (2) clinical or radiographic evidence of rupture or impend-
ing rupture; (3) symptomatic presentation with an aortic diameter
greater than 5 cm or documented rapid aortic enlargement; and (4)
symptomatic branch vessel occlusion with distal organ ischemia,
as determined by clinical symptoms or laboratory testing.
Patients were excluded if arterial access was inadequate (small
[,7 mm] iliac or femoral arteries) or if the PIT was located within
1 cm from the left common carotid artery origin. Patients with Mar-
fan syndrome or other connective tissue disorders were excluded
(contraindication to stent–grafting in our institutional review board
protocols), but a 16-year-old patient with type IV (vascular type) Eh-
lers–Danlos syndrome who was initially seen with aortic rupture and
paraplegia was treated on a compassionate use basis. Three patients
were first seen with a propagating (.20 cm) genuine aortic dissec-
tion caused by traumatic aortic disruption at the level of the ligamen-
tum, but patients with isolated traumatic tears and localizedThe Journal of Thotraumatic pseudoaneurysms were excluded. Spontaneous dissection
was the etiology in the remaining 12 cases.
Preprocedural Imaging
All patients underwent thin-slice CTA with 3-dimensional recon-
structions to determine the exact location of the PIT, the distance
from the PIT to the left subclavian and carotid arteries, the lengths
and diameters of the diseased aortic segments, the morphologic
characteristics of the proximal and distal landing zones, the diame-
ters of the true and false lumens, and the mechanism of end-organ
malperfusion. The stent–graft was oversized by 10% to 15% relative
to the proximal true lumen to make it just slightly larger than the
distal aortic arch diameter. When possible, the stent–graft was
deployed at least 20 to 40 mm beyond the PIT to ensure adequate
wall contact and a tight circumferential seal.
Stent–graft Devices
First-generation stent–grafts were custom fabricated from modified
Gianturco Z stents (Cook Medical Inc, Bloomington, Ind) that were
wired together and then covered with a woven polyester graft (Bos-
ton Scientific Corporation, Natick, Mass). A 20F to 24F pusher-rod
sheath delivery system (Cook) was used for deployment of the first-
generation devices in the initial 8 patients. Second-generation, com-
mercially manufactured Gore Excluder or TAG stent–grafts became
available later and were used in the remaining 8 patients. These
devices consist of a self-expanding nitinol exoskeleton lined with
expanded polytetrafluoroethylene graft material, require the intro-
ducer sheath be inserted only as far as the abdominal aorta, are ad-
vanced over a coaxial wire, and are rapidly deployed by a drawstring
mechanism that releases a constraining shroud.
Details of stent–graft deployment techniques have been de-
scribed previously.1,6 With the patient under general anesthesia in
an operating room-equipped catheterization laboratory with a Sie-
mens 2300 Imaging System (Siemens Medical Systems, Inc, Ultra-
sound Group, Issaquah, Wash), transesophageal echocardiography,
angiography, and occasionally intravascular ultrasonography were
used to define the aortic true and false lumens. After arterial access
was gained through either the femoral or iliac artery, a hydrophilic
guide wire was advanced into the aortic arch and exchanged for
a stiff wire; the delivery system dilator–sheath was then advanced
into the aortic true lumen, and the stent–graft was advanced to the
target to cover the PIT completely. After optimal positioning of
the device, the stent–graft was deployed. Ballooning of the stent–
graft was performed only if a large type IA proximal endoleak
was documented, and only at the proximal landing zone. When
needed, a second stent–graft was placed. Angiography confirmed
the absence of endoleaks and determined the perfusion status of pre-
viously ischemic arterial beds.
Follow-up and Definitions
Before discharge, at 3, 6, and 12 months, and then annually thereaf-
ter, we attempted to obtain follow-up CTA scans for all patients.
Aortic diameter was assessed just below the distal end of the
stent–graft. Clinical status was ascertained by contacting the patients
or their primary physicians. Causes of death were determined by re-
viewing death certificates and, when available, autopsy reports.
Technical success was defined as exclusion of the false lumen
with reperfusion of previously ischemic, mesenteric, renal, or lower
extremity arterial beds. Treatment failure was defined as a compositeracic and Cardiovascular Surgery c Volume 136, Number 2 425
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leaks, late device failure, the necessity for reintervention, late aortic-
related death, and all sudden, unexplained late deaths, as previously
advocated by our group. Continuous variables are expressed as
mean 6 SD and median values; important rates and fractions are
expressed with 70% confidence limits. The Kaplan–Meier method
generated actuarial survival estimates, which are reported SE, which
approximates the 70% confidence limits. All statistical analyses
were performed with SPSS software (SPSS, Inc, Chicago, Ill).
Results
Eleven of the 16 patients were male, and 5 were female.
Average age was 57 6 19 years (range 16–88 years), and
hypertension was present in 15 of 16 patients. Demographic
data are summarized in Table 1. Mean follow-up interval was
366 36 months, ranged from 3 to 93 months, and was 100%
complete. Eight patients remained at risk at 3 years, and 6
remained at risk at 5 years. A total of 48 patient-years of fol-
low-up was available for analysis.
Early Outcome
Aortic access was achieved in all patients, all devices were
deployed in the intended position, and the main PIT was
covered in each patient. In 2 patients, a second stent–graft
was placed proximally to eliminate a type I endoleak. No im-
mediate open surgical conversions were necessary. Stent–
graft characteristics and aortic dimensions are listed in
Table 2. Early mortality was 25% 6 11%; all 4 patients
died within 6 days of stent–grafting. Two patients almost
certainly died of aortic rupture (sudden death consistent
with exsanguination without autopsy). Two patients died of
fulminant multiorgan failure, 1 each after extensive bowel re-
section and amputation of a gangrenous leg.
Early Morbidity
Four patients required concomitant true lumen stenting of aor-
tic branches because of static occlusion. This treatment in-
cluded renal, mesenteric, or iliac artery stenting, as detailed
in Table 3. Early false-lumen thrombosis was documented in
2 cases, and the false lumen thrombosed subsequently in 2 ad-
ditional cases. No new stroke or paraplegia occurred, but pre-
procedural paraplegia in 1 patient did not improve. One patient
had a temporary paraparesis, which resolved within 20 days.
After rehabilitation, at the time of follow-up, this patient could
walk with a cane. Four patients (25%) required surgical arterial
repair, including iliofemoral bypass in 1 case. Pulmonary com-
plications occurred in 2 patients. Renal insufficiency (defined
as serum creatinine.3.5 mg/dL) occurred in 8 patients (50%),
often after severe preprocedural renal ischemia; 3 of these pa-
tients required temporary hemodialysis.
Late Outcome
Follow-up was 100% complete, and it was encouraging that
there were no late deaths. Actuarial survival was 73%6 11%
at 1, 3, and 5 years (Figure 1); furthermore, no stent migra-
tion, dislocation, or erosion was documented. One patient
with a retrograde A dissection in which the false lumen in
TABLE 1. Demographic patient data
Patient Sex Age (y) Comorbidities Clinical Indicators
1 Male 43 HPB Refractory HPB, chest pain
2 Male 53 HPB Refractory HPB, leg
ischemia
3 Male 46 HPB Chest pain, mesenteric
ischemia, claudication
4 Male 37 HPB Refractory HPB, renal
ischemia
5 Female 40 HPB Mesenteric ischemia
6 Male 16 HPB/delirium Refractory chest pain,
pleural effusion
7 Male 54 Ehlers–Danlos Refractory HPB, chest pain
8 Female 40 HPB Mesenteric ischemia
9 Female 74 HBP/renal
fibrodysplasia
Refractory HPB, chest pain
10 Male 65 HPB Renal ischemia
11 Female 58 HPB Refractory HPB, chest pain
12 Male 83 Trauma Extensive pleural effusion
13 Male 87 Trauma Large pleural effusion
14 Male 62 Trauma Leg ischemia
15 Male 74 HPB Large pleural effusion
16 Female 75 HPB Refractory HPB, chest pain
HBP, Arterial hypertension.
TABLE 2. Stent–graft and aortic (combined true and false













1 Custom made 2, 28 3 75 45 48
2 Custom made 38 3 50 50 53
3 Custom made 36 3 45 45 50
4 Custom made 32 3 50 23 45
5 Custom made 30 3 77,5 38 Died
6 Custom made 36 3 50 40 Died
7 Custom made 35 3 70 35 Surgery
8 Custom made 26 3 75 36 39
9 Excluder 31 3 100 41 50
10 Excluder 31 3 100 42 40
11 Excluder 26 3 100 26 Died
12 Excluder 40 3 150,
40 3 100
44 45
13 Excluder 34 3 150 45 32
14 Excluder 31 3 150 32 Died
15 Excluder 37 3 200 48 47
16 TAG 34 3 125 38 40
Excluder and TAG are registered trademarks of W. L. Gore & Associates,
Inc, Flagstaff, Ariz.
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CDthe ascending aorta had thrombosed required repeated tho-
racic aortic stent–grafting 3 months later because of a proxi-
mal type I endoleak with enlargement of the false lumen.
Balloon dilatation of the extension stent–graft tore the distal
dissection flap, which created a large communication be-
tween the true and false lumens. After this patient underwent
open surgical graft replacement of his distal arch and proxi-
mal descending thoracic aorta, he recovered uneventfully.
Endoleaks
According to the most recent CTA scan, 1 patient had a per-
sistent type I endoleak (Figure 2); absence of any demonstra-
ble expansion of the false lumen permitted continued
expectant observation for this patient. An increase in aortic
diameter (Figure 3) was documented in 1 case (patient 9). Ac-
tuarial freedom from treatment failure (broadly defined as
aortic rupture, migration or failure of the mechanical device,
any necessity for reintervention, late aortic-related death, or
any sudden, unexplained late death) was 67% 6 14% at 1,
3, and 5 years (Figure 4).
Discussion
Patients with life-threatening complications of acute type B
aortic dissection remain a high-risk subset.13,17,18 Open sur-
gical mortality risk is high compared to emergency endovas-
cular stent–grafting, as we first reported in 1999.6 Even with
endovascular treatment,19,20 mortality risk can still be high
(25% in this small series), with some deaths due to irrevers-
ible infarction of distal end organs. Our stent–graft strategy is
Figure 1. Kaplan–Meier actuarial patient survival estimates. Five-
year survival was 76%6 9%. Nine patients remained alive and at
risk 5 years after the procedure.
TABLE 3. Summary of malperfused arteries and late status of aortic false lumen
Patient Malperfused branch arteries Stenting of branch arteries
Thrombosis of
false lumen*
1 0 0 Complete
2 Left renal and right common iliac Wall stent, left renal and right common iliac Complete
3 Supramesenteric Wall stent, supramesenteric Partial
4 Right renal 0 Patent
5 Both common iliac and supramesenteric Wall stent, supramesenteric and left and right common iliac died
6 Left renal and right femoral 0 died
7 0 0 Partial
8 Celiac mesenteric, left renal, and right iliac Palmaz stent, right iliac Patent
9 0 0 Partial
10 Left femoral 0 Complete
11 0 Died died
12 0 0 Complete
13 0 0 Partial
14 Supramesenteric, both common iliac, and both renal Infrarenal thrombectomy died
15 0 0 Partial
16 0 0 Partial
*According to last computed tomographic scan.
Figure 2. Evolution with time of type I and type II endoleaks. Most
endoleaks spontaneously resolved or were manageable by endo-
vascular means, but 1 patient required surgical graft replacement
3 months later for a proximal type 1 endoleak.
The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 2 427
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acute malperfusion complications will allow the patient to
be resuscitated and clinically stabilized,,21-23 after which
more definitive treatment, possibly including open surgical
repair, can be accomplished with lower cumulative risk.
Our therapeutic goals for patients with acute dissections are
to reperfuse the lower body and prevent rupture, not neces-
sarily to eliminate all flow into the false lumen.
It is difficult to know with certainty the results of endovas-
cular stent–graft repair in patients with complicated acute
type B aortic dissections for a host of reasons. Most reports
contain both complicated and uncomplicated cases, as well
as mixed cases of acute and chronic dissections. Furthermore,
most physicians in Europe and South America consider
stent–grafting too risky until at least 2 weeks have passed
since presentation; such patients with subacute dissections
constitute a naturally selected subset. To define complicated
acute type B dissection,6,24,25 we considered the threat of
continued aortic expansion or rupture and the extent and
severity of distal end-organ ischemia. Indicators of high
risk included ongoing chest or abdominal pain despite opti-
mal medical therapy, rapid dilation of the aortic false lumen,
increasing pleural effusion accompanied by pain, radio-
graphic signs of rupture or impending rupture, evolution of
clinical symptoms, and laboratory markers associated with
gut ischemia accompanied by signs of compromised visceral
perfusion on CTA scan. It is generally accepted that these
criteria define a high-risk subgroup of acute type B aortic dis-
section that requires emergency treatment. Risk of rupture is
usually obvious from progressive radiologic signs, clinical
instability, and inability to control the pain. Intestinal ische-
Figure 3. Comparison between thrombosed false lumen and
change in aortic diameter. There was no relationship between
thrombosed false lumen and increasing aortic diameter.428 The Journal of Thoracic and Cardiovascular Surgery c Aumia, however, may progress more insidiously, with results
of abdominal examination potentially remaining unremark-
able until visceral infarction has become established. At
this stage, gut salvage may not be possible, even after
successful abdominal aortic reperfusion. Despite early
stent–graft deployment, restoration of adequate branch artery
true-lumen perfusion with bare stents, and prompt surgical
bowel resection when necessary, death was not preventable
in cases of irreversible infarction of two or more vascular
beds. At an earlier stage, when reperfusion can still salvage
important end organs, patients with malperfusion and evolv-
ing visceral ischemia could be identified. A third scenario
exists where there is severe malperfusion, usually involving
the kidneys, without clinical symptoms. Loss of adequate
perfusion to one kidney, despite satisfactory urine output
from the contralateral functioning kidney, can eventually re-
sult in loss of a functioning kidney.17
In general, three treatment strategies are available. Direct
open surgical aortic graft replacement through a left thoracot-
omy can redirect blood flow into the true lumen and remove
the aortic segment with the most trauma. This, however, has
historically been associated with high operative risk,13 is
invasive, and requires cardiopulmonary bypass and profound
hypothermia for an open proximal anastomosis in the
arch.10,11 Further, immediate adequacy of distal reperfusion
is not easily assessable,18 which may necessitate additional
downstream catheter interventional treatment. Endovascular
stent–graft repair similarly redirects blood flow into the
true lumen, and immediate assessment of the adequacy of
distal perfusion is obtained with aortography. Nonreperfused
organs cut off by static branch obstruction can then be
quickly reperfused with catheter-based dissection flap fenes-
tration or branch true-lumen stenting.6,24 Finally, balloon
fenestration of the dissection flap and stenting from the aortic
true or false lumen into the true lumen of the ischemic branch
Figure 4. Actuarial freedom from treatment failure (including aor-
tic rupture, device mechanical fault, reintervention, late aortic-
related death, or sudden, unexplained late death).gust 2008
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before the availability of thoracic aortic stent–grafts. All
these techniques may be effective in the short term, and
each is associated with different degrees of invasiveness,
effectiveness, and attendant morbidity. Open surgical aortic
repair remains the treatment of choice for patients with major
arch involvement, those in whom the PIT is too proximal to
allow stent–grafting, and those with Marfan syndrome or
other connective tissue disorders.
Limitations of thoracic aortic stent–grafting clearly exist.
Multiple reentry fenestrations are usually present in the distal
descending thoracic and abdominal aorta, allowing continued
perfusion of the false lumen. Although flow through these
communications may prevent complete thrombosis of the
aortic false lumen, these fenestrations are usually smaller
than the PIT and neither cause aortic true-lumen obstruction
nor lead to acute rupture of the false lumen. Follow-up stud-
ies from Mei University in Japan have shown that late serious
aortic complications occur after stent–grafting for aortic dis-
section, for example, delayed intimal tears caused by the
stent–graft or migration of the stent–graft away from the aor-
tic wall along the lesser curve of the distal arch.25,26 Careful,
continuous follow-up is essential indefinitely to ensure stabil-
ity of the stent–graft, persistent patency of important aortic
tributaries, and the aortic true- and false-lumen dimensions.
The 25% incidence of complete false-lumen thrombosis ob-
served in our experience was higher than that reported after
surgical repair of patients with acute type A dissections,
but a comparison of the likelihood of false-lumen thrombosis
or enlargement is handicapped by the small sample size in
this report. Again, our therapeutic goal for patients with acute
type B dissections is not so much to eliminate all blood flow
in the false lumen as to reperfuse the lower body quickly and
prevent thoracic aortic rupture. A persistent proximal type I
endoleak, which does not necessarily preclude early success
because reperfusion of severely ischemic abdominal end or-
gans is one of the key therapeutic goals, may result in late
failure from progressive false-lumen expansion. Type II en-
doleaks, which may be confused with natural flap reentry fen-
estrations, however, do not connote failure and usually can be
followed up observationally unless they result in progressive
false-lumen aneurysmal dilation. In this experience, aortic di-
ameter in the absence of an endoleak remained stable at mid-
term follow-up in most cases. Additional follow-up of
a larger number of patients, however, is clearly mandatory
to elucidate the long-term results of stent–grafting in patients
with complicated acute type B dissections.
Although stent–graft repair is an attractive alternative
because it is less invasive, angiography requires the use of io-
dinated contrast, which can exacerbate preexisting ischemic
renal injury. Technologic limitations also exist. Half of the
deaths in this series were due to aortic rupture and represent
treatment failure. The acutely dissected aorta and flap are
exceptionally fragile and thin, calling for special, disease-The Journal of Thorspecific endograft designs that currently are lacking. The
ideal stent–graft for acute dissection should be able to be
fixed securely in the distal arch without hooks, must be soft
and flexible to allow maneuvering within the arch without
creation of a retrograde type A dissection, and must conform
readily to the sharp curvature of the distal arch to avoid prox-
imal endoleaks. The ideal stent–graft for acute dissections
should also have sufficient radial strength to expand the
true lumen, thus promoting false-lumen thrombosis without
further intimal flap injury. Advances in stent–graft technol-
ogy and newer disease-specific stent–grafts should translate
into better results in the future. Finally, avoiding coverage
of the distal half of the descending thoracic aorta is important
in minimizing the likelihood of paraplegia.
In summary, emergency endovascular thoracic aortic
stent–graft repair for patients with complicated acute type
B dissections saves lives and is effective to 5 years. Promis-
ing observations in this report with extended follow-up
include the absence of late deaths and the reasonable stability
of the stent–graft. Stent–grafting rapidly reverses life-threat-
ening malperfusion in cases of true-lumen collapse and prob-
ably minimizes the risk of rupture as well. Because of the
high-risk nature of this patient population, it is unrealistic
to expect that the mortality risk will approach zero; if the
life-threatening consequences of acute distal malperfusion
can be reversed early enough and the patient stabilized,
more patients will survive the early high risk phase. Then
the patient can be followed up clinically and the dissected
aorta monitored carefully with serial scans. If false-lumen
enlargement occurs, delayed open surgical repair can be per-
formed in elective circumstances with a reasonably low risk.
Finally, the long-term (5–10 years) effectiveness and durabil-
ity of thoracic stent–grafting for acute type B aortic dissection
will remain unknown until the results of larger studies with
long-term follow-up are available.
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